Literature DB >> 2563519

Tamoxifen and the uterus and endometrium.

P Neven, X De Muylder, Y Van Belle, G Vanderick, E De Muylder.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2563519

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  21 in total

1.  Gynaecological effects of tamoxifen.

Authors:  S M Ismail
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

Review 2.  My approach to the interpretation of endometrial biopsies and curettings.

Authors:  W G McCluggage
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

Review 3.  The demise of the D&C.

Authors:  C J Seamark
Journal:  J R Soc Med       Date:  1998-02       Impact factor: 5.344

Review 4.  Tamoxifen: a review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer.

Authors:  H M Bryson; G L Plosker
Journal:  Pharmacoeconomics       Date:  1993-07       Impact factor: 4.981

5.  Tamoxifen and the uterus.

Authors:  P Neven; X De Muylder; Y Van Belle; R Campo; G Vanderick
Journal:  BMJ       Date:  1994-11-19

6.  The effects of intermittent progesterone upon tamoxifen inhibition of tumor growth in the 7,12-dimethylbenzanthracene rat mammary tumor model.

Authors:  D F Gibson; D A Johnson; S M Langan-Fahey; M K Lababidi; W H Wolberg; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1993-09       Impact factor: 4.872

7.  Tamoxifen and cancer of the endometrium.

Authors:  G O'Connell; A Arnold
Journal:  CMAJ       Date:  1993-06-15       Impact factor: 8.262

Review 8.  Tamoxifen and secondary tumours. An update.

Authors:  N Wilking; E Isaksson; E von Schoultz
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

9.  Pathology of endometrium treated with tamoxifen.

Authors:  S M Ismail
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

10.  Phase I study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue.

Authors:  H Pujol; J Girault; P Rouanet; S Fournier; J Grenier; J Simony; J B Fourtillan; J L Pujol
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.